DF/HCC Kidney Cancer SPORE

DF/HCC 肾癌孢子

• 批准号: 7910615
• 负责人: Michael Benjamin Atkins
• 金额: $ 230万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-18 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7910615
• 关键词: DF; HCC; Kidney; Cancer; SPORE

This application represents the renewal of the Specialized Program of Research Excellence in Kidney Cancer originating from the Kidney Cancer Program of the Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Kidney Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Clinical Correlations of WTX Inactivation in Wilms Tumor; 2) Validation of RCC biomarkers for early disease detection and response to targeted therapy; 3) Acquired Resistance to VEGF Receptor Blockade: Underlying Mechanism and Therapeutic Options; 4), Targeting the PI3-Kinase/Akt Pathway in RCC: Mechanism of Action and Opportunities for Rational Combination Therapy; and 5) Adoptive Immunotherapy for Renal Carcinoma Using Dendritic Cell/tumor Fusions. These projects are integrated by three cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; and 3) Tissue Acquisition, Pathology and Clinical Data, This SPORE application outlines a Development Research Program which includes a plan for selection and review of new projects and examples of 4 recently funded and 3 projects that could be considered for future support. We also include a Career Development Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Kidney Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with kidney cancer.

该应用程序代表了肾脏癌症研究卓越的专业计划，该计划源自达纳 - 法伯哈佛癌中心（DF/HCC）和贝丝以色列执事医疗中心的肾脏癌症计划。 DF/HCC肾癌孢子包括来自哈佛大学的所有医院的调查员 - 贝丝以色列执事医疗中心，达纳 - 法伯癌研究所，马萨诸塞州综合医院，杨百翰和妇女医院以及儿童医院医疗中心作为哈佛公共卫生学院。通过此应用程序支持了五个主要项目，包括：1）WILMS肿瘤中WTX失活的临床相关性； 2）验证RCC生物标志物以早期疾病检测和对靶向治疗的反应； 3）获得了对VEGF受体阻滞的抵抗力：基本机制和治疗选择； 4），针对RCC中的PI3-激酶/AKT途径：作用机理和理性组合疗法的机会；和5）使用树突状细胞/肿瘤融合的肾癌的产物免疫疗法。这些项目由三个核心整合。这些是：1）行政，评估和计划； 2）生物统计学； 3）组织获取，病理和临床数据，该孢子应用概述了一项开发研究计划，其中包括选择和审查新项目的计划，以及最近有4个最近资助的新项目的计划和3个可以考虑未来支持的项目。我们还包括一项职业发展计划，概述了对肾脏癌的才华横溢的年轻调查人员进行识别，支持和审查的机制。 DF/HCC肾癌孢子的总体目标是将生物学和技术进步转化为肾癌患者的临床意义进步。